{"pmcid": 115849, "prompt_strategy": "zeroshot", "model": "gemini-3-pro-preview", "extractions": [{"outcome": "Discontinuation due to lack of efficacy", "intervention": "etoricoxib 90 mg once daily", "comparator": "naproxen 500 mg twice daily", "intervention_group_size": 353, "comparator_group_size": 181, "intervention_events": 44, "comparator_events": 19, "outcome_type": "binary"}, {"outcome": "Patient global assessment of disease activity", "intervention": "etoricoxib 90 mg once daily", "comparator": "placebo", "intervention_group_size": 353, "comparator_group_size": 357, "outcome_type": "continuous"}, {"outcome": "investigator global assessment of disease activity", "intervention": "etoricoxib 90 mg once daily", "comparator": "placebo", "intervention_group_size": 353, "comparator_group_size": 357, "outcome_type": "continuous"}, {"outcome": "Tender joint count", "intervention": "etoricoxib 90 mg once daily", "comparator": "placebo", "intervention_group_size": 353, "comparator_group_size": 357, "outcome_type": "continuous"}, {"outcome": "Swollen joint count", "intervention": "etoricoxib 90 mg once daily", "comparator": "placebo", "intervention_group_size": 353, "comparator_group_size": 357, "outcome_type": "continuous"}, {"outcome": "Patient global assessment of pain", "intervention": "etoricoxib 90 mg once daily", "comparator": "placebo", "intervention_group_size": 353, "comparator_group_size": 357, "outcome_type": "continuous"}, {"outcome": "Health Assessment Questionnaire disability", "intervention": "etoricoxib 90 mg once daily", "comparator": "placebo", "intervention_group_size": 353, "comparator_group_size": 357, "outcome_type": "continuous"}, {"outcome": "Serum C-reactive protein", "intervention": "etoricoxib 90 mg once daily", "comparator": "placebo", "intervention_group_size": 353, "comparator_group_size": 357, "outcome_type": "continuous"}, {"outcome": "ACR20 responder criteria", "intervention": "etoricoxib 90 mg once daily", "comparator": "placebo", "intervention_group_size": 353, "comparator_group_size": 357, "outcome_type": "binary"}, {"outcome": "Discontinuation due to lack of efficacy", "intervention": "etoricoxib 90 mg once daily", "comparator": "placebo", "intervention_group_size": 353, "comparator_group_size": 357, "intervention_events": 44, "comparator_events": 90, "outcome_type": "binary"}, {"outcome": "Patient global assessment of disease activity", "intervention": "naproxen 500 mg twice daily", "comparator": "placebo", "intervention_group_size": 181, "comparator_group_size": 357, "outcome_type": "continuous"}, {"outcome": "investigator global assessment of disease activity", "intervention": "naproxen 500 mg twice daily", "comparator": "placebo", "intervention_group_size": 181, "comparator_group_size": 357, "outcome_type": "continuous"}, {"outcome": "Tender joint count", "intervention": "naproxen 500 mg twice daily", "comparator": "placebo", "intervention_group_size": 181, "comparator_group_size": 357, "outcome_type": "continuous"}, {"outcome": "Swollen joint count", "intervention": "naproxen 500 mg twice daily", "comparator": "placebo", "intervention_group_size": 181, "comparator_group_size": 357, "outcome_type": "continuous"}, {"outcome": "Patient global assessment of pain", "intervention": "naproxen 500 mg twice daily", "comparator": "placebo", "intervention_group_size": 181, "comparator_group_size": 357, "outcome_type": "continuous"}, {"outcome": "Health Assessment Questionnaire disability", "intervention": "naproxen 500 mg twice daily", "comparator": "placebo", "intervention_group_size": 181, "comparator_group_size": 357, "outcome_type": "continuous"}, {"outcome": "Serum C-reactive protein", "intervention": "naproxen 500 mg twice daily", "comparator": "placebo", "intervention_group_size": 181, "comparator_group_size": 357, "outcome_type": "continuous"}, {"outcome": "ACR20 responder criteria", "intervention": "naproxen 500 mg twice daily", "comparator": "placebo", "intervention_group_size": 181, "comparator_group_size": 357, "outcome_type": "binary"}, {"outcome": "Discontinuation due to lack of efficacy", "intervention": "naproxen 500 mg twice daily", "comparator": "placebo", "intervention_group_size": 181, "comparator_group_size": 357, "intervention_events": 19, "comparator_events": 90, "outcome_type": "binary"}, {"outcome": "Patient global assessment of disease activity", "intervention": "etoricoxib 90 mg once daily", "comparator": "naproxen 500 mg twice daily", "intervention_group_size": 353, "comparator_group_size": 181, "outcome_type": "continuous"}, {"outcome": "investigator global assessment of disease activity", "intervention": "etoricoxib 90 mg once daily", "comparator": "naproxen 500 mg twice daily", "intervention_group_size": 353, "comparator_group_size": 181, "outcome_type": "continuous"}, {"outcome": "Tender joint count", "intervention": "etoricoxib 90 mg once daily", "comparator": "naproxen 500 mg twice daily", "intervention_group_size": 353, "comparator_group_size": 181, "outcome_type": "continuous"}, {"outcome": "Swollen joint count", "intervention": "etoricoxib 90 mg once daily", "comparator": "naproxen 500 mg twice daily", "intervention_group_size": 353, "comparator_group_size": 181, "outcome_type": "continuous"}, {"outcome": "Patient global assessment of pain", "intervention": "etoricoxib 90 mg once daily", "comparator": "naproxen 500 mg twice daily", "intervention_group_size": 353, "comparator_group_size": 181, "outcome_type": "continuous"}, {"outcome": "Health Assessment Questionnaire disability", "intervention": "etoricoxib 90 mg once daily", "comparator": "naproxen 500 mg twice daily", "intervention_group_size": 353, "comparator_group_size": 181, "outcome_type": "continuous"}, {"outcome": "Serum C-reactive protein", "intervention": "etoricoxib 90 mg once daily", "comparator": "naproxen 500 mg twice daily", "intervention_group_size": 353, "comparator_group_size": 181, "outcome_type": "continuous"}, {"outcome": "ACR20 responder criteria", "intervention": "etoricoxib 90 mg once daily", "comparator": "naproxen 500 mg twice daily", "intervention_group_size": 353, "comparator_group_size": 181, "outcome_type": "binary"}, {"outcome": "patients discontinued due to lack of efficacy", "intervention": "etoricoxib 90 mg once daily", "comparator": "placebo", "intervention_group_size": 353, "comparator_group_size": 357, "intervention_events": 44, "comparator_events": 90, "outcome_type": "binary"}, {"outcome": "patients discontinued due to lack of efficacy", "intervention": "naproxen 500 mg twice daily", "comparator": "placebo", "intervention_group_size": 181, "comparator_group_size": 357, "intervention_events": 19, "comparator_events": 90, "outcome_type": "binary"}], "errors": []}
